Idorsia Ltd (19T.SG)
| Previous close | 19.80 |
| YTD return | N/A |
| Expense ratio (net) | N/A |
| Category | N/A |
| Last cap gain | N/A |
| Morningstar rating | N/A |
| Morningstar risk rating | N/A |
| Sustainability rating | N/A |
| Net assets | N/A |
| Beta (5Y monthly) | N/A |
| Yield | N/A |
| 5y average return | N/A |
| Holdings turnover | N/A |
| Last dividend | N/A |
| Average for category | N/A |
| Inception date | N/A |
GlobeNewswireIdorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with chronic insomnia, will be presented at Sleep Europe 2024 – the 27th Congress of the European Sleep Research Society (ESRS), taking place in Seville, Spain, September 24–27, 2024. The following posters will be presented: Lederer K, et al. Efficacy and safety of daridorexant in patients with chroni
- GlobeNewswire
New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024
Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil, Switzerland – September 5, 2024Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2024, taking place in Chicago, Illinois, September 5–8, 2024. On March 19, 2024, aprocitentan was approved as TRYVIO™ in the US, with availability planned for Q4 202
- GlobeNewswire
Amended terms of Idorsia’s 2024 convertible bonds become effective
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal was filed – the amended terms of Idorsia’s outstanding convertible bonds, originally maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds) have become effective. The cut-off date in respect of the consent fee is today, which means that bondholders holding the Bonds on – or who have purchased the
